Key Takeaways Canaan secured $72 million in new funding from Galaxy Digital, Weiss Asset Management, and Brevan Howard Digital. The […] The post Institutional Giants Inject $72 Million into Canaan’s Bitcoin Mining Expansion appeared first on Coindoo.Key Takeaways Canaan secured $72 million in new funding from Galaxy Digital, Weiss Asset Management, and Brevan Howard Digital. The […] The post Institutional Giants Inject $72 Million into Canaan’s Bitcoin Mining Expansion appeared first on Coindoo.

Institutional Giants Inject $72 Million into Canaan’s Bitcoin Mining Expansion

2025/11/06 04:05
Key Takeaways
  • Canaan secured $72 million in new funding from Galaxy Digital, Weiss Asset Management, and Brevan Howard Digital.
  • The fresh capital will reinforce its balance sheet and reduce reliance on at-the-market raises.
  • The company is focusing solely on Bitcoin mining infrastructure after exiting the AI hardware business.
  • Canaan’s shares jumped nearly 9% in intraday Nasdaq trading following the news.

The investment, completed through a registered direct offering, involved the sale of 63.7 million American depositary shares at $1.13 apiece. Canaan said the capital injection will help strengthen its financial position and limit future reliance on short-term fundraising, signaling a strategic pivot toward long-term stability.

A Vote of Confidence from Institutional Heavyweights

The involvement of Galaxy, Weiss, and Brevan Howard underscores a growing institutional appetite for direct exposure to Bitcoin’s backbone industries. Rather than betting on tokens or ETFs, these firms are now targeting the companies that manufacture and maintain the tools behind the network’s security.

Canaan’s new investors represent some of the most established names bridging traditional finance and digital assets. For Canaan, the deal reflects what it called “a shift toward partnerships with fundamentals-focused investment groups,” replacing the more opportunistic capital raises that defined its earlier years.

A Veteran Miner Reinforces Its Core

Founded in 2013, Canaan was among the first to commercialize ASIC-based mining machines and quickly became synonymous with its flagship Avalon line. While many of its peers diversified into AI chip production and cloud computing to offset market volatility, Canaan has opted to do the opposite — return to its roots.

The company announced in mid-2025 that it would end all AI-related hardware projects, citing a renewed focus on mining systems and infrastructure. Chairman and CEO Nangeng Zhang called this a “strategic recommitment” to what Canaan does best: powering the Bitcoin network through advanced, efficient ASIC design.

READ MORE:

Litecoin Tests a Critical Zone as ETF Approval and Charlie Lee’s Return Fuel Hopes

Building Momentum in the U.S.

Canaan has been quietly expanding its footprint in North America, completing a pilot production run in the United States earlier this year. The goal: to speed up equipment delivery to U.S.-based miners and strengthen relationships in the region now responsible for nearly 38% of global Bitcoin hashrate.

That decision is already paying off. In October, Canaan’s stock climbed over 26% after it revealed a 50,000-rig order from an unnamed U.S. customer — its largest deal in more than three years. The company said such orders validate its decision to stay laser-focused on Bitcoin mining instead of chasing the AI trend.

Strategic Positioning for the Next Cycle

The latest investment effectively gives Canaan the breathing room it needs to scale operations and prepare for the next market expansion. Industry observers view this round as not just a cash infusion but a signal that deep-pocketed investors see long-term value in the mining ecosystem — especially as Bitcoin’s next halving approaches.

With Galaxy Digital and Brevan Howard Digital now on board, Canaan is positioned to strengthen its supply chain, accelerate ASIC innovation, and deepen its reach in the Western mining landscape. The company’s share price reaction — up nearly 9% in Tuesday’s trading — suggests the market agrees that this is more than just another capital raise.


The information provided in this article is for educational purposes only and does not constitute financial, investment, or trading advice. Coindoo.com does not endorse or recommend any specific investment strategy or cryptocurrency. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.

The post Institutional Giants Inject $72 Million into Canaan’s Bitcoin Mining Expansion appeared first on Coindoo.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26